These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8372725)

  • 1. Toxicity of antimalarial drugs in rheumatoid arthritis.
    Rynes RI
    Agents Actions Suppl; 1993; 44():151-7. PubMed ID: 8372725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of anti-malarials in rheumatoid arthritis--the American experience.
    Khraishi MM; Singh G
    Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More thoughts about antimalarials: should one prescribe chloroquine?
    Esdaile JM
    J Rheumatol; 1999 Sep; 26(9):1868. PubMed ID: 10493663
    [No Abstract]   [Full Text] [Related]  

  • 5. Ophthalmologic monitoring for antimalarial toxicity.
    Sfikakis PP; Mavrikakis M
    J Rheumatol; 2004 May; 31(5):1011-2; author reply 1012. PubMed ID: 15124272
    [No Abstract]   [Full Text] [Related]  

  • 6. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
    Aletaha D; Smolen JS
    J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK; Furst DE
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimalarials in rheumatic diseases.
    Day RO; Sambrook P; Champion GD; Graham GG
    Aust N Z J Med; 1982 Dec; 12(6):645-9. PubMed ID: 6962718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular toxicity of hydroxychloroquine.
    Tehrani R; Ostrowski RA; Hariman R; Jay WM
    Semin Ophthalmol; 2008; 23(3):201-9. PubMed ID: 18432546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Macular complications of synthetic antimalarials. Apropos of a case].
    Ducousso F; Ballion JC; Kovalski JL; Labrouze JM; Bazin S; Bourguignon G; Saliou G
    J Fr Ophtalmol; 1995; 18(8-9):553-8. PubMed ID: 7560802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal toxicity due to antimalarials: frequency and risk factors.
    Palma Sánchez D; Rubio Velazquez E; Soro Marín S; Reyes García R
    Reumatol Clin; 2013; 9(5):259-62. PubMed ID: 23707434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis.
    Aletaha D; Kapral T; Smolen JS
    Ann Rheum Dis; 2003 May; 62(5):482-6. PubMed ID: 12695166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risks of antimalarial retinopathy, azathioprine lymphoma and methotrexate hepatotoxicity during the treatment of rheumatoid arthritis.
    Urowitz MB; Lee P
    Baillieres Clin Rheumatol; 1990 Aug; 4(2):193-206. PubMed ID: 2032296
    [No Abstract]   [Full Text] [Related]  

  • 20. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.